For the past few years, MannKind Corporation has been generating the majority of its revenue from its only product: Afrezza. But, by the end of May, the company could have two more products added to its portfolio, thanks in large part to MannKind’s $10 million acquisition of Zealand Pharma’s V-Go product, announced May 17. There…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
